News about Clinical Trials

Adcendo Receives FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Tiffany-01 is an ongoing first-in-human Phase I multicenter, open-label, dose escalation study of ADCE-T02 as a monotherapy in patients with advanced solid tumors.

Clinical Trials | 27/02/2025 | By Aishwarya

Inventiva and Hepalys Pharma Initiate Clinical Development Program of Lanifibranor in Japan

The trial is conducted pursuant to the terms of the exclusive licensing agreement entered into in 2023 between Inventiva and Hepalys to develop and commercialize lanifibranor in Japan and South Korea.

Clinical Trials | 21/02/2025 | By Aishwarya

AlzeCure Gets EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856

This funding will support AlzeCure’s planned Phase IIa study of NeuroRestore ACD856 in Alzheimer’s patients.

Clinical Trials | 19/02/2025 | By Aishwarya

Selkirk Pharma Launches ClinFAST to Expedite Fill/Finish for Clinical Trials

Selkirk Pharma maintains an on-site inventory of ISO-sized vials, stoppers, filling assemblies, and excipients, reducing the lead time required for sourcing materials.

Clinical Trials | 14/02/2025 | By Aishwarya

Philogen Completes Patient Enrollment of Phase III FIBROSARC Trial in STS

All ongoing Fibromun trials remain on track with their expected timelines.

Clinical Trials | 05/02/2025 | By Aishwarya |  404

Exigent Research and ConcertAI to Integrate CARAai Precision Trial Solutions

The technology suite will be tailored and fully integrated to all Exigent sites and all EMRs and powered by the CARAai™ platform.

Clinical Trials | 04/02/2025 | By Aishwarya

Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan

In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Clinical Trials | 01/02/2025 | By Abha

Corsair Pharma Collaborates with InstantGMP to Enhance Quality for Clinical Trials

Corsair Pharma is revolutionizing pulmonary arterial hypertension (PAH) treatment with its first product candidate: a prodrug of treprostinil delivered via a proprietary transdermal patch.

Clinical Trials | 30/01/2025 | By Aishwarya

Tris Pharma Reveals Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol

This dual-NMR agonist has the potential to deliver significant pain relief comparable to opioids with minimized risk of significant side effects, dependence and addiction by leveraging the body’s pain biology modulation processes, synergizing the analgesic and safety characteristics of the NOP receptor with the analgesic advantages of the MOP receptor.

Clinical Trials | 23/01/2025 | By Aishwarya

Advarra Launches Comprehensive Solution to Improve Collaboration on Clinical Trials

The new offering combines the Longboat technology acquired by Advarra in 2020, which now has over 225,000 users, with Advarra's study startup delivery program and industry-adopted single sign-on capabilities.

Clinical Trials | 22/01/2025 | By Aishwarya